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 Cancer Stem Cells in Prostate 
Cancer: Implications for 
Targeted Therapy 
regarding PCa and also for treatment resistance and disease 
progression once clinical cure is achieved. Therapies target-
ing CSCs might therefore lead to more effective cancer treat-
ments, divergent from a traditional anti-proliferative ap-
proach, based on tumor bulk reduction accompanied by 
CSC-specific inhibition. Here, we focus on reviewing the his-
torical perspective as well as concepts regarding stem cells 
and CSCs in PCa. In addition, we will report possible strategies 
and new clinical approaches that address the CSC-based con-
cept of tumorigenesis in PCa.  © 2017 S. Karger AG, Basel 
 Introduction 
 Prostate cancers (PCa) are highly heterogeneous tu-
mors containing multiple independent and genetically 
distinct clones  [1–4] . The cellular heterogeneity might 
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 Abstract 
 Prostate cancer (PCa) is the most frequently diagnosed cancer 
in men and the second most common cause of cancer-related 
mortality among men in the developed world. Conventional 
anti-PCa therapies include surgery, radiation, hormonal abla-
tion, and chemotherapy. Despite increasing efforts, these 
therapies are not effective for patients with advanced and/or 
metastatic disease. In most cases, cancer therapies fail due to 
an incomplete depletion of tumor cells, resulting in tumor re-
lapse. The cancer stem cell (CSC) hypothesis is an emerging 
model that explains many of the molecular characteristics of 
oncological disease as well as the tendency of cancers to re-
lapse, metastasize, and develop resistance to conventional 
therapies. CSCs are a reservoir of cancer cells that exhibit prop-
erties of self-renewal and the ability to reestablish the hetero-
geneous tumor cell population. The existence of PCa stem 
cells offers a theoretical explanation for many uncertainties 
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pose clinical challenges due to therapy resistance and tu-
mor relapse.
 Current treatments for clinically localized PCa are 
based on surgical excision of the prostate (radical 
 prostatectomy) and radiation therapy  [2–5] . By con-
trast, advanced-stage PCa is usually treated with 
 androgen-deprivation therapy, which reduces tumor 
burden and/or circulating prostate-specific antigen 
(PSA) to low or undetectable levels  [2–6] . Patients with 
advanced PCa initially respond to hormone therapy; 
however, due to androgen mechanisms, a significant 
number of patients will progress to recurrent castration-
resistant PCa and eventually die from metastatic disease 
 [2–7] .
 Resistance to androgen deprivation and subsequently 
to chemotherapy remains the main cause for treatment 
failure and mortality in patients with PCa  [7–10] . Treat-
ment resistance in cancer may result from the survival of 
a subpopulation of tumor cells. These cells may subse-
quently lead to relapse, disease progression, and eventu-
ally systemic disease  [3, 7] . This is particularly true for 
PCa since these tumors present a heterogeneous popula-
tion of cells  [3, 7–9] .
 One premise that explains this cellular heterogeneity 
and treatment resistance is the “cancer stem cell” (CSC) 
hypothesis  [4, 7], which postulates that human tumor 
cancers cells are organized hierarchically, and only a sub-
set of cancer cells are endowed with tumor-initiating and 
long-term tumor-propagating capability  [3, 8] . These tu-
mor-initiating cells are termed CSCs and possess many 
phenotypic and functional properties associated with 
normal stem cells  [3, 7] .
 Therefore, it is not surprising that many PCa stem cell 
(PCSC) populations have now been identified and that 
emerging evidence suggests a critical role for them in dis-
ease relapse and progression  [1, 2, 4, 11] .
 Stem Cells 
 The discovery of hematopoietic stem cells emerged 
from the study of hematopoiesis  [12] . Hematopoietic 
cells have the capacity for unlimited self-renewal as well 
as differentiation into all lineages of mature cells and 
thereby sustain a permanent source of blood cells  [13] . 
The physiological function of “normal” stem cells is to 
maintain tissue homeostasis, tissue regeneration and re-
pair, as well as controlling proliferation and differentia-
tion necessary for the proper functioning of organs. In 
addition to hematopoietic stem cells, adult stem cells have 
been identified in bone marrow, muscle, intestine, brain, 
skin/hair follicles, heart, lung, mammary glands, and 
prostate  [14–16] .
 Adult stem cells reside in a quiescent state, regulated 
by cell cycle regulatory genes (p21, p18, p63)  [13, 17] . 
When they leave the quiescent state, these cells self-renew 
and differentiate into other cells (usually restricted to the 
respective tissue type) controlled by intrinsic and extrin-
sic regulatory mechanisms  [12, 17, 18] .
 Prostate and Prostate Stem Cells 
 The prostate gland is an endodermal tissue that devel-
ops during late embryogenesis from the anterior urogen-
ital sinus epithelium in a dihydrotestosterone-dependent 
process  [2, 19–21] . In early embryonic development, the 
prostate is comprised of a multilayered epithelium sur-
rounded by mesenchyma  [2, 19, 22] .
 There are 3 main cell types that constitute normal ma-
ture prostatic epithelium: luminal secretory cells, prolif-
erative basal cells, and neuroendocrine cells  [4, 19, 23, 24] . 
These cells are morphologically distinguishable by the ex-
pression of specific markers  [25, 26] .
 The embryonic origin of the prostate (from the uro-
genital sinus) may explain the large presence of prostate 
stem cells within this organ  [27] . The existence of a stem 
cell subpopulation in the prostate was first identified in 
the 1980s  [22] . The most widely accepted model propos-
es the presence of stem cells in the basal cell compartment 
 [18, 19, 25, 26, 28] . Additionally, prostate epithelial cells 
(with an intermediate phenotype) can be observed in 
adult prostates, suggesting that the developmental rela-
tionship between basal and secretory cells is maintained 
into adult life and that the capacity for renewal and dif-
ferentiation is still present  [18, 19, 25, 26] .
 Basal cells typically show higher proliferation rates 
than secretory cells. In studies of androgenic suppression, 
the prostatic epithelium (consisting mainly of secretory 
cells) undergoes apoptosis  [22, 23, 29] . In contrast, basal 
cells are able to survive in low androgen environments, 
demonstrating that the high renewal capacity of the pros-
tatic epithelium is due to the basal cells, which reconsti-
tute the secretory cell compartment in response to andro-
gen readministration  [9, 22, 23, 29] . The preferential sur-
vival of basal cells led to the hypothesis that the stem cells 
reside within the basal cell layer of the prostate gland  [9, 
22] .
 Although the model in which renewal and differentia-
tion of prostatic epithelium occurs in the basal cells is cur-
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rently widely accepted, there are some authors who pro-
pose a different model in which the secretory cells are 
capable of sustaining self-renewal and differentiation, 
without any contribution from basal cells  [30, 31] .
 The tumorigenic properties of prostate stem cells, 
 isolated from patients undergoing radical prostatec-
tomy, have been studied in vitro and in vivo (by im-
planting  them into immunocompromised animals) 
assessing  their capacity for extensive proliferation, 
self- renewal, differentiation, and invasion ( Fig. 1 )  [32, 
33] .
 Fig. 1. Prostate cancer (PCa) cells–associated and PCa stem cells–associated pathways. 
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 PCa Stem Cells 
 Cancer is recognized as a heterogeneous disease with 
a variety of phenotypes. This heterogeneity is an intrinsic 
characteristic that contributes to therapy failure. One the-
ory that explains tumor heterogeneity is the CSC hypoth-
esis  [4, 7, 34–36] . This hypothesis postulates that only a 
small subpopulation of cancer cells within a tumor pos-
sesses the capacity to regenerate the tumor. This subset of 
tumor-propagating cells, defined as CSCs, share a num-
ber of characteristics with normal stem cells such as self-
renewal, high proliferative potential, and the capacity to 
generate the heterogeneous lineages of cancer cells that 
make up the tumor  [4–8, 36, 37] . Thus, the CSC hypoth-
esis suggests that tumor cell lineages are hierarchical with 
a unique self-renewing population of cells at the top of 
that hierarchy ( Fig. 1 )  [4] .
 Research into CSCs has progressed rapidly and con-
comitantly with advances in stem cell biology, novel meth-
ods for their identification, purification, and characteriza-
tion have been developed as well as the creation of animal 
models  [4, 6, 8, 34, 37] . The first demonstration of CSCs 
in any cancer was in 1977 when Bonnet and Dick  [12] 
demonstrated the initiation of human acute leukemia my-
eloid from a population of cells expressing cell surface 
markers CD44 + and CD38 – in NOD/SCID mice. This sug-
gested that normal primitive cells are targets for leukemic 
transformation  [38] . CSCs have since been reported in a 
wide spectrum of solid tumors including breast, pancreas, 
colon, lung, brain, and prostate  [4, 8, 35] .
 CSCs express various specific surface markers, includ-
ing cell-adhesion molecules (e.g., CD24, CD44, CD133, 
and hyaluronic acid), HER2, aldehyde dehydrogenase 
(ALDH) activity and transcription factors including 
OCT-4 and SOX-2 at different levels from the bulk tumor 
population  [35, 37, 39, 40] . Human prostatic cells (within 
the basal layer) express cell surface marker CD133 (hema-
topoietic stem cell marker) and stem cell antigen-1, which 
reveals their stem cell properties  [9, 28, 41, 42] .
 PCa cells are highly organized and only a subset of 
these cells retains the capacity for tumor initiation and 
long-term tumor-propagating activity, supporting the 
CSC hypothesis  [3, 5] . These tumor-initiating cells dis-
play phenotypic and functional features characteristic of 
normal prostate stem cells and are involved in tumor ini-
tiation, metastasis, and drug resistance  [5] . Thus, PCa 
may originate from stem cells or dividing progenitor cells 
that become CSCs as a consequence of genetic mutations 
or changes in the tumor microenvironment  [3, 5] . PCSCs 
could account for resistance to androgen-deprivation 
therapy-resistant cells that give rise to castrate resistant 
PCa (CRPC), since they possess self-renewal and tumor-
propagating capabilities and also lack or have very low 
androgen receptors expression  [4, 28] .
 The cellular origins of PCa are still under debate 
( Fig. 1 ). The most common prostate tumors express high 
levels of K8, K18, androgen receptors, and PSA but low 
levels of basal cell markers such as p63, suggesting that the 
disease arises from luminal cells  [32, 42, 43] . Other stud-
ies suggest that the disease is derived from intermediate 
cells that have acquired the ability to self-renew  [32] .
 Isolation of PCSCs has been reported by several differ-
ent groups. Collins et al. [44] first isolated a CSC popula-
tion from patients undergoing radical prostatectomy. 
The PCSCs displayed a significant capacity for self-re-
newal as well as the ability to regenerate the phenotypi-
cally mixed populations of non-clonogenic cells  [10] . The 
PCSCs had a CD44/α2β1 high /CD133 + phenotype and 
showed high clonogenic and invasive capacity, while phe-
notypically basal and genetically unstable  [44, 45] .
 Rajasekhar et al. developed a study for better under-
standing PCSCs. They found that CSCs expressing hu-
man pluripotent stem cell marker TRA-60-1 + /CD151 + /
CD166 + had high capacity for self-renewal and differen-
tiation, and were able to recapitulate the original tumor 
heterogeneity in serial xenotransplantations, indicating a 
tumor cell hierarchy in PCa development  [46] .
 Recently, it has been shown that 55% of prostate tu-
mors harbor a gene fusion between the prostate-specific 
TMPRSS2 gene and the ERG oncogene (TMPRSS2:ERG) 
 [47, 48] . Polson et al. [49] demonstrated the presence and 
expression of TMPRSS2:ERG in PCSCs, which would 
provide ERG-driven survival advantages. Moreover, 
ALDH + PCa cells have been shown to exhibit several CSC 
characteristics such as clonogenicity, migration, tumori-
genicity, and propensity to form metastases in vivo  [3, 
10] . Furthermore, PCSCs have also been shown to express 
Oct4 and Sox2 along with Nanog in several PCa tissue 
samples  [3, 28] .
 Recent reports indicate that miRNAs play a significant 
role in CSC regulation, including PCSCs, and may ex-
plain some of the molecular regulatory mechanisms of 
CSCs  [50] . The aberrant expression of miRNAs in cancer 
suggests that they function as either oncogenes or tumor-
suppressor genes  [51] . miRNAs such as miR-470, miR-
296, and miR-134 are involved in regulating target genes 
essential for pluripotency and stem-cell function includ-
ing Oct4, NANOG, and SOX2  [50, 52, 53] .
 Moreover, a miRNA expression signature specific for 
CSC populations has been confirmed in several cancers 
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including PCa. The majority of miRNAs discovered in 
PCa act as, or target, tumor-suppressor genes. These miR-
NAs are underexpressed in the PCSCs leading to the dis-
inhibition of various stem-cell properties, such as clono-
genic expansion, tumor regeneration, and metastasis  [50, 
52] .
 One important capability of CSCs is the epithelial–
mesenchymal transition (EMT). This event plays an 
 important role in promoting cell migration and the devel-
opment of metastasis. Several miRNAs, such as the 
 miRNA-200 family, miRNA132/212, miRNA-205, and 
miRNA-203 promote the epithelial state and have been 
shown to inhibit the EMT  [50, 51, 54, 55] .
 Thus, the identification of PCSCs and their cell-specif-
ic markers is a crucial step in understanding PCa onto-
genesis and in developing new therapeutic approaches 
 [15, 37, 56, 57] .
 CSCs as Therapeutic Targets in PCa 
 The CSC hypothesis provides an explanation for tu-
mor initiation, progression, conventional therapy-re-
sistance, recurrence, and metastasis  [4, 6–8, 34, 35, 37, 
58] . CSCs display self-renewal capacity, resistance to 
cytotoxic agents (e.g., chemotherapy or androgen abla-
tion in prostate), competency to proliferate, and the 
ability to be both clonogenic and tumorigenic  [19, 37, 
56, 58] .
 The CSC hypothesis suggests that standard therapies 
have incomplete and temporary effects on the bulk tu-
mor, and that tumors tend to relapse due to the multiple 
resistant mechanisms existing in CSCs  [15, 37, 56] . CSCs 
therefore constitute a cellular reservoir that persists after 
anti-proliferative therapies  [12, 37, 48, 59] . The inherent 
plasticity of CSCs makes them more adept to survive in a 
foreign environment. Additionally, genetic instability in 
CSCs likely provides a selective advantage in adapting to 
foreign sites  [15] .
 Current therapeutic approaches for PCa remain insuf-
ficient for some patients with progressive disease. 
 Although tumors initially respond well to androgen re-
duction, the duration of response is short, approximately 
12–33 months. At this point, a population of cells resis-
tant to androgen-deprivation therapy emerges  [43] . Even 
after chemotherapy (and after a period of good clinical 
response) there is further clinical progression  [43] .
 Thus, the development of PCSC-specific anticancer 
drugs constitutes an attempt to innovate in the treatment 
in PCa  [60, 61] .
 Specific Targeting of Pathways Involved in PCSCs 
 Signaling pathways that are upregulated in stem cells 
and that are specific to their functionality represent a 
hypothetical target for drugs addressing CSCs. The fact 
that many forms of cancer share the same expression 
pattern in certain pathways suggests that targeting of 
CSC signaling pathways may be an extraordinary thera-
peutic strategy. Currently, the pathways that demon-
strate therapeutic potential in PCSCs are the Hedgehog 
(Hh), Wnt, Notch, and NF-κB pathways. Also, ABC 
transporters and tumor microenvironment seem to be 
potential targets for CSC depletion ( Fig. 1 )  [35, 37, 59, 
62] .
 Hh Pathway 
 The Hh pathway is critical in embryogenesis but is sig-
nificantly less active in adults. However, it plays a crucial 
role in regulating CSCs in various human cancers includ-
ing PCa by regulating target genes involved in prolifera-
tion, survival, metastasis, and auto-regulation  [37, 63–
65] . Furthermore, the Hh pathway promotes multidrug 
resistance by increasing the transcription of the ABC 
transporter proteins ABCB1 and ABCG2 in PCa  [63, 64] . 
Thus, the inhibition of the Hh signaling pathway may re-
sult in the depletion of CSCs  [37, 63] .
 Hh inhibitors have shown promising results in vitro. 
Sonidegib (LDE-225) inhibits spheroid formation and 
self-renewal of CSCs by suppressing the pluripotency-
maintaining factors Nanog, Oct4, Sox2, and c-Myc and 
also inhibits tumor growth in PCa cells  [63] . GANT-61 is 
a cell-permeable hexahydropyrimidine compound that is 
an inhibitor of GLI-mediated gene transactivation. 
 GLI-mediated transcription is the final step in the Hh sig-
naling pathway; therefore, GANT-61 halts Hh pathway 
effects. GANT-61 has shown selective inhibition of GLI1 
and GLI2 in many cancer cell lines. In a xenograft mouse 
model of PCa, GANT-61 reduced tumor growth and pro-
liferation and strongly reduced the expression of PTCH1 
mRNA  [66, 67] . These inhibitors are currently in preclin-
ical development in numerous tumor types including 
PCa  [68, 69] .
 At the clinical level, the Food and Drug Administration 
has already approved the first Hh inhibitor for clinical use, 
vismodegib (GDC-0449)  [62, 64, 68–70] . Five clinical tri-
als are currently testing Hh inhibitors in PCa treatment 
( Table 1 ). In the NTC01163084 study, vismodegib is being 
tested in stages IIA and IIB PCa as a neoadjuvant treat-
ment in conjunction with the anti-androgen leuprolide 
acetate. Itraconozale is being used in hormone-sensitive 
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PCa (NCT018787331) and in combination with Orteronel 
(NCT02054793) for CRPC in patients previously treated 
with curative intent. LDE225 is being evaluated in high-
risk patients as a neoadjuvant treatment (NCT02111187) 
and finally Vismodegib (NCT02115828) is being tested in 
patients with metastatic lesions.
 Wnt Signaling Pathway 
 The Wnt signaling pathway is involved in multiple bi-
ological processes including embryogenesis, develop-
ment, cell proliferation, cell survival, and cell differentia-
tion. The canonical Wnt signaling pathway plays a critical 
role in self-renewal and maintenance of stem cells  [37] . In 
Table 1.  Clinical trials targeting PCa cells-associated pathways
Clinical trial Drug Target population Objectives Approval 
stage
Associated 
pathway
NCT01163084 LHRHa vs. 
LHRHa plus 
vismodegib 
followed by 
surgery
Clinical stage T1c or T2 with 
high-grade disease (Gleason’s 
8–10) on initial biopsy and PSA 
>10 ng/mL, or clinical stage 
T2b-T2c with Gleason’s grade ≥7
Compare tumor involvement in both arms Phase 1, 
phase 2
Hedgehog
NCT01787331 Itraconazole Patients with non-castrate, 
non-metastatic, biochemically 
relapsed PCa after prior definitive 
local therapy
Determine the proportion of patients who achieve 
≥50% decline in PSA
Phase 2 Hedgehog
NCT02111187 LDE225 vs. no 
treatment 
(before surgery)
High risk PCa patients (Gleason ≥8; 
PSA >20 ng/mL; clinical stage ≥T3)
Change from baseline in tissue GLI1 expression 
pathological effect of pre-surgical treatment with 
LDE225
Phase 1 Hedgehog
NCT02054793 Itraconazole and 
orteronel
Castrate resistant PCa To determine the safety and tolerability of the 
combination regimen: orteronel + itraconazole
Phase 1, 
phase 2
Hedgehog
NCT02115828 Vismodegib mCRPC with accessible metastatic 
lesions for tumor biopsy
Proportion of mCRPC patients treated with 
vismodegib who achieve a pharmacodynamics 
response in tumor biopsies
Phase 0 Hedgehog
NCT02655952 Foxy-5 Metastatic PCa (for which no 
curative therapy exists)
Establish the recommended dose for a clinical 
phase II study and enable further development of 
foxy-5 as a first in class antimetastatic cancer drug
Phase 1 Wnt
NCT02020291 Foxy-5 Metastatic PCa (for which no 
curative therapy exists)
Determine the safety, tolerability and pharmaco 
safety of foxy-5
Phase 1 Wnt
NCT01608867 OMP-54F28 Solid tumors including PCa 
(confirmed malignancy that is 
metastatic or unresectable)
Determine the safety, pharmacokinetics and 
immunogenicity of OMP-54F28 in subjects with 
previously treated solid tumors
Phase 1 Wnt
NCT01200810 Notch signalling 
pathway inhibitor 
RO4929097 + 
bicalutamide
Recurrent PCa stage IV PCa Compare time for PSA progression Phase 1 Notch
NCT02757365 Aspirin 
Levofloxacin
PSA >10 ng/mL; prostate biopsy 
showing BPH with infiltrated 
lymphocytes
Evaluate the role of aspirin in PCa prevention Phase 2 NF-κB
NCT00118092 Tanespimycin Hormone refractory PCa patients Evaluate drug response in terms of: PSA response; 
overall survival; disease specific survival
Phase 2 NF-κB
NCT01695473 BKM120 High-risk (confirmed by prostate 
biopsy), localized PCa
Determine the proportion of men with 
downstream target inhibition of PI3K in prostate 
tumor tissue
Phase 2 NF-κB
PCa, prostate cancer; PSA, prostate specific antigen; mCRPC, metastatic castration-resistant Pca; BPH, benign prostatic hyperplasia.
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PCa, the Wnt signaling pathway has been linked to the 
progression of androgen-independent disease and bone 
metastasis  [45, 48, 71] .
 The inhibition of the Wnt pathway results in the down-
regulation of CSCs and constitutes an interesting target 
for treatment  [37] . The Wnt pathway can be inhibited by 
Wnt inhibitory factors, Wnt antagonists, or via condi-
tional knockout of β-catenin  [37] .
 A number of therapeutic agents targeting the Wnt 
pathway are under investigation and monoclonal anti-
bodies (mAb) against the Wnt cascade have been tested 
with promising anti-tumor activity  [35, 72] . A small mol-
ecule inhibitor, Wnt inhibitor 3289–8625, has also been 
shown to inhibit the growth of PC3 PCa cells in vitro 
 [73] .
 Vantictumab (OMP-18R5), a monoclonal antibody 
that blocks canonical Wnt/β-catenin signaling by binding 
to 5 of the FZD receptors, and LGK974 (a small molecule 
inhibitor of porcupine) are being tested in solid tumors 
in combination with chemotherapeutic drugs such as 
docetaxel and paclitaxel  [72–75] . LGK974 is a potent in-
hibitor of porcupine – a membrane-bound O-acyltrans-
ferase that is required for the palmitoylation of Wnt li-
gands and which is crucial in the process of Wnt ligand 
secretion  [76] .
 Foxy-5 is another Wnt-inhibiting agent that is being 
tested in 2 clinical trials. It is a hexapeptide that activates 
Wnt-5a-mediated signaling. Increased Wnt-5a signal-
ing may inhibit endothelial tumor cell migration and 
 invasion and may decrease metastasis. Foxy-5 has been 
tested in metastatic PCa patients for whom standard 
therapies were not effective (NCT02020291 and 
NCT02655952); however, the results of these studies are 
not yet known.
 Finally, OMP-54F28, a fusion protein of the FZD8 li-
gand-binding domain that binds to all Wnt ligands, is 
now being tested in a phase I trial for treatment of solid 
tumors including PCa (NCT01608867)  [72] .
 Notch Signaling Pathway 
 The Notch signaling pathway regulates stem cell main-
tenance and differentiation. It contributes to angiogene-
sis, proliferation, differentiation, and apoptosis  [37, 77] . 
In hypoxic microenvironments, the hypoxia-inducible 
factor activates the Notch pathway and the expression of 
transcription factors such as Oct4. This pathway controls 
stem cell self-renewal and pluripotency, enabling CSCs to 
survive and proliferate  [77] .
 The Notch signaling pathway is often over-activated in 
cancers, including PCa  [37] . The silencing of Notch ex-
pression in mouse prostate inhibits morphogenesis, 
growth, and differentiation during development. In addi-
tion, it inhibits prostate regrowth triggered by hormone 
replacement in castrated mice  [78] .
 Several agents targeting Notch signaling are being tri-
aled including the γ-secretase inhibitor (GSI), siRNAs, 
and mAb against Notch receptors and Notch ligands 
 [79] .
 GSI was initially tested in T-Acute Lymphocytic Leu-
kemia cell lines and later in prostate, breast, and lung cell 
lines and was found to suppress cancer growth  [80] . 
Notch inhibitors have been tested in combination with 
conventional cytostatic agents or targeted drugs in phase 
I or phase II evaluations  [79] .
 There are currently 2 clinical trials studying the effects 
of GSI in cancer. One of these is specific for PCa patients 
(NCT01200810;  Table 1 ). This study combines the anti-
androgen bicalutamide with GSI (RO4929097) in pa-
tients whose PCa recurs after surgery or radiation and 
compares the time to PSA progression in both arms  [80] .
 NF-κB Pathway 
 The NF-κB pathway is upregulated in CSCs and is im-
portant for apoptosis resistance in tumor cells  [35, 48, 77, 
81] . It has been shown that the activation of NF-κB sig-
naling in PCa cells correlates with PCa progression, che-
moresistance, recurrence, and metastasis  [82, 83] . Thus, 
inhibiting NF-κB can suppress chemoresistance, and 
mediate antitumor responses while enhancing the sensi-
tivity of tumor cells to other anticancer drugs  [82] . Sev-
eral studies have focused on targeting the NF-κB path-
way on its own or in combination with conventional 
agents  [84] .
 Bortezomib is a proteasome-inhibitor that was first 
approved for use in multiple myeloma. While its effects 
are complex, it has an overall inhibitory effect on the 
 NF-kB pathway. Preclinical studies have shown that bort-
ezomib induces cell growth inhibition and apoptosis in a 
broad range of cancer cell lines in vitro and in various 
animal xenograft models, including PCa  [84] .
 Phase I, II, and III clinical studies, demonstrate that 
bortezomib causes chemo/radio-sensitization and can 
overcome drug resistance when combined with conven-
tional therapeutic agents or radiation. In patients with ad-
vanced androgen-independent PCa, bortezomib alone 
shows anti-tumor activity (phase I)  [85] . However, vari-
ous phase II trials investigating bortezomib alone or in 
combination with prednisone or docetaxel in patients 
with CRPC have shown disappointing results. Patients 
with biochemical recurrence after definitive local therapy 
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for PCa, treated with bortezomib alone before androgen 
deprivation, however have shown stabilization of PSA 
levels  [84, 85] .
 IKK inhibitors are another class of NF-kB inhibiting 
agents. The IKK-inhibitors PS1145 and BMS345541 have 
shown promising results by inducing cellular apoptosis, 
inhibiting invasion of PCa cells in vitro, and reducing 
proliferation in androgen receptor-expressing PCa cell 
lines  [84] .
 There are currently 3 clinical trials targeting the NF-
κB pathway in PCa ( Table 1 ). NCT02757365 is evaluat-
ing the efficiency of aspirin in preventing the occurrence 
of PCa. The rationale for this trial is that inflammation 
may play an important role in the development of PCa, 
by unknown mechanisms. Aspirin has already been 
shown to prevent several inflammation-related tumors. 
In this study, investigators are exploring the effects of 
anti-inflammatory therapy on progression from inflam-
mation to PCa and from androgen-dependent PCa to 
CRPC.
 NCT00118092 is a phase II trial that is evaluating the 
effect of 17-(allylamino)-17-demethoxygeldanamycin, a 
heat shock protein 90 (HSP90) inhibitor used in the treat-
ment of patients with metastatic PCa who did not re-
spond to previous hormone therapy. The enrollment for 
this trial was prematurely stopped because of insufficient 
PSA response  [86] .
 Finally, clinical trial NCT01695473 is testing a potent 
and highly selective pan-class I PI3K inhibitor (BKM120) 
that acts downstream of NF-kB. It is being tested in pa-
tients with high-risk, localized PCa  [87] .
 ABC Transporters 
 CSCs express high levels of ABC transporters that pro-
tect CSCs from chemotherapeutic agents, thereby con-
tributing to multidrug resistance  [9, 35, 37] . ABCG2 in-
hibitors make CSCs more susceptible to chemotherapeu-
tic agents, thereby allowing the use of drugs that were 
previously used unsuccessfully  [14, 35, 88] .
 The first P-gp efflux pump inhibitor was verapamil, a 
widely used calcium channel blocker  [89] . Simultaneous 
treatment with verapamil and antitumor drugs, such as 
vincristine, vinblastine, docetaxel, and paclitaxel has 
shown promising therapeutic effects  [35, 89] . Verapamil, 
shows anti-proliferative action in LNCaP cells through 
the inhibition of K + channels, suggesting that P-gp could 
be a target for new pharmacological agents directed 
against PCa cell proliferation  [90] .
 Cyclosporin A (CsA) is also a Pgp inhibitor that has 
antitumor effects in various cancers including PCa. Lee et 
al. [91] demonstrated that CsA might have a survival ben-
efit in metastatic PCa that relapses and progresses to 
CRPC. It has also been shown that a combination of CsA 
with EGFR or AKT inhibitors may have clinical applica-
tion due to its efficiency in inhibiting cancer growth. An-
other study demonstrated the potential of CsA in inacti-
vating the NFATc1 (nuclear factor of activated T-cells) in 
hormone-naive PCa and also in CRPC  [92] .
 The estrogen-receptor modulator tamoxifen has been 
evaluated in a preliminary phase II study to access its 
therapeutic efficacy in metastatic PCa patients who have 
progressed in spite of classical endocrine therapy using 
LHRH-analogs and/or anti-androgens. Results showed a 
decrease of greater than 50% in PSA serum levels within 
the first 2 months of therapy in 20% of the patients  [93] .
 PSC 833 is an immunosuppressive agent that inter-
feres with the function of the multi-drug resistance pump, 
and consequently plays a key role in chemoresistance. 
This drug, combined with estramustine, etoposide, keto-
conazole, suramin, or vinorelbine, has demonstrated syn-
ergistic effects in PCa cell lines  [94] .
 In spite of these successes, many early-phase I/II stud-
ies attempting Pgp inhibition using first-generation, non-
specific Pgp inhibitors, such as verapamil, CsA, and 
tamoxifen failed to demonstrate an improvement in over-
all drug efficacy, primarily due to poor potency. With the 
development of second-generation agents like PSC833 
(valspodar) and VX-710 (biricodar), there has been an 
increase in potency. However, results remain unpromis-
ing  [95] .
 Recent studies using chemotherapeutic drugs in com-
bination with modulators of ABC drug transporters have 
shown some benefit  [89, 96] . As yet, however, there are 
no clinical trials targeting PCSCs using ABC transporter 
inhibitors.
 Microenvironment 
 Normal stem cells reside in a specialized cellular loca-
tion known as the niche, which provides a microenviron-
ment that maintains a stem-like state. Studies suggest that 
CSCs also rely on a niche, the CSC niche, which controls 
self-renewal and differentiation  [22, 39, 97, 98] . The CSC 
niche provides a microenvironment that maintains the 
balance between quiescence and self-renewal and re-
sponds dynamically to physiological requirements essen-
tial to homeostasis  [22] . This interaction is supported by 
the fact that loss of the niche environment leads to the loss 
of CSCs  [97] .
 The tumor microenvironment also protects CSCs 
from drug-induced apoptosis, and is responsible for drug 
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resistance  [35, 59, 98–100] . The CSC microenvironment 
is responsible for abnormal signaling pathway activation, 
including the Wnt, Hh, and TGF-β pathways  [101] . In 
addition, the microenvironment is hypothesized to be in-
volved in metastasis by the induction of the EMT, leading 
to the dissemination and invasion of other tissues  [97, 
101] .
 Currently, several novel therapies that disrupt signal-
ing pathways within tumor microenvironments are un-
der investigation. These agents disrupt the “crosstalk” be-
tween epithelial cells, stromal cells, and the ECM neces-
sary for PCa progression and metastasis  [35, 102] .
 Discussion and Conclusion 
 PCa is a highly prevalent disease and is of biological, 
clinical, social, and also economic interest, motivating a 
growing body of translational research. Tumor recur-
rence, disease progression, and metastasis remain obsta-
cles to improving survival rates in patients with PCa.
 Advanced cancer is a major problem in clinical oncol-
ogy. Progressive, recurrent, and metastatic cancers are 
clinically challenging. Driven by the need for novel and 
improved treatment modalities for advanced PCa, the de-
velopment of therapeutic strategies targeting PCSCs is 
becoming a major focus of research. The CSC concept of 
tumorigenesis suggests that therapies specifically target-
ing CSCs may lead to more effective cancer treatments 
and this has provided a stimulus for new therapeutic 
strategies beyond the traditional anti-proliferative agents 
 [33, 103, 104] . This new approach is based on the concept 
of tumor bulk reduction accompanied by CSC-specific 
inhibition.
 Recent advances in CSC biology have accelerated 
translational research aimed at depleting CSCs. Targeted 
therapies are being developed for cell surface markers, 
signaling pathways, and the CSC cellular microenviron-
ment (niche). Angiogenesis is a cornerstone of the tumor 
microenvironment and is important in CSC survival and 
drug resistance.
 Preclinical data have demonstrated that targeting 
pathways involved in CSC homeostasis has meaningful 
results. Hh, Wnt, Notch, and NF-κB pathway inhibitors 
inhibit CSC renewal, suppress pluripotency of stem cell 
factors (Oct4, Sox2, c-Myc, and Nanog), and inhibit tu-
mor growth both in vivo and ex vivo.
 These exciting preclinical results have led to the 
 development of clinical trials targeting these specific 
pathways. A majority of ongoing clinical trials are 
phase II studies. Together, these studies address all stag-
es of PCa disease (localized, high-risk, hormone-refrac-
tory, and metastatic) as well as disease prevention 
 (aspirin).
 Currently, there are active clinical trials addressing all 
the pathways mentioned in this manuscript. Wnt path-
way inhibitors (Foxy-5 and OMP-54F28) are being tested 
in patients with metastatic disease for whom all other 
therapies have been ineffective (phase I studies). This 
makes intuitive sense given that the Wnt pathway is in-
volved in androgen-independent mechanisms and bone 
metastasis. Hh pathway inhibitors have received more at-
tention from clinicians and industry with a significant 
number of ongoing clinical trials. This may be justified, 
given the promising results obtained with vismodegib in 
basal cell carcinoma and other cancers. In PCa, vismo-
degib is being studied as a neoadjuvant for localized dis-
ease as well as in metastatic disease.
 Studies using aspirin and itraconazole, as inhibitors 
of the Hh and NF-κB pathways, respectively, represent 
an attempt to harness known drugs with few side effects. 
In these studies, the Hh pathway has been targeted using 
itraconazole alone or in combination with orteronel. 
The use of orterenol to block male sex hormone produc-
tion was hypothesized to increase reliance on the Hh 
pathway, thus creating a synergistic effect. Unfortunate-
ly, this study was closed prior to enrollment. The single 
clinical trial targeting Notch signaling was also termi-
nated early.
 These pathways have been shown to be important in 
PCa, promoting tumor growth through CSC prolifera-
tion, creating a favorable microenvironment for tumor 
growth and metastasis, and contributing to therapy resis-
tance.
 The targeting of PCSCs via the Wnt, Hh, Notch, 
 NF-κB pathways as well as the targeting of the CSC niche 
is an exciting area of research and may become an impor-
tant addition to traditional treatment regimens. Al-
though the clinical results have not yet lived up to pre-
clinical hopes, there are still many avenues to be explored. 
Targeting PCSCs in multidrug combined regimens will 
shift the paradigm of PCa treatment and might be a 
breakthrough in the treatment of both early and progres-
sive disease.
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